NYSE:EW Edwards Lifesciences - EW Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. $80.76 +1.21 (+1.52%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$79.37▼$81.0250-Day Range$74.34▼$84.5152-Week Range$67.13▼$131.10Volume2.75 million shsAverage Volume4.13 million shsMarket Capitalization$48.95 billionP/E Ratio33.10Dividend YieldN/APrice Target$88.95 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Edwards Lifesciences MarketRank™ ForecastAnalyst RatingHold2.39 Rating ScoreUpside/Downside10.1% Upside$88.95 Price TargetShort InterestHealthy2.12% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.74Based on 7 Articles This WeekInsider TradingSelling Shares$7.90 M Sold Last QuarterProj. Earnings Growth12.70%From $2.52 to $2.84 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.67 out of 5 starsMedical Sector87th out of 989 stocksSurgical Appliances & Supplies Industry7th out of 20 stocks 3.2 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.39, and is based on 8 buy ratings, 9 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $88.95, Edwards Lifesciences has a forecasted upside of 10.1% from its current price of $80.76.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.12% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.6 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Edwards Lifesciences this week, compared to 6 articles on an average week.Search InterestOnly 28 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,902,704.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions80.35% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.70% in the coming year, from $2.52 to $2.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 33.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 33.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.56.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.76. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 8.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edwards Lifesciences (NYSE:EW) StockEdwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.Read More Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Edwards Lifesciences (NYSE:EW)March 18, 2023 | americanbankingnews.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells $343,579.45 in StockMarch 25, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 17, 2023 | marketwatch.comEdwards Lifesciences Corp. stock rises Thursday, outperforms marketMarch 16, 2023 | americanbankingnews.comMichael A. Mussallem Sells 19,875 Shares of Edwards Lifesciences Co. (NYSE:EW) StockMarch 9, 2023 | finance.yahoo.com5 big analyst cuts: Tesla stock slumps on Berenberg downgrade | Pro RecapMarch 8, 2023 | msn.comWells Fargo Downgrades Edwards Lifesciences (EW)March 6, 2023 | finance.yahoo.comEDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSISMarch 25, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 3, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Edwards Lifesciences (EW)March 2, 2023 | finance.yahoo.comWhy Is Edwards Lifesciences (EW) Down 2% Since Last Earnings Report?March 1, 2023 | marketwatch.comEdwards Lifesciences Corp. stock falls Wednesday, underperforms marketMarch 1, 2023 | marketwatch.comEdwards Lifesciences Corp. stock rises Monday, outperforms marketMarch 1, 2023 | marketwatch.comEdwards Lifesciences Corp. stock outperforms competitors on strong trading dayFebruary 27, 2023 | finance.yahoo.comHumana (HUM) Exits Business Line to Focus More on Core UnitsFebruary 20, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Gains on Innovation, Margin GrowthFebruary 19, 2023 | finance.yahoo.comWith 87% ownership, Edwards Lifesciences Corporation (NYSE:EW) boasts of strong institutional backingFebruary 6, 2023 | markets.businessinsider.comCredit Suisse Keeps Their Hold Rating on Edwards Lifesciences (EW)February 6, 2023 | za.investing.comRaymond James softens on Edwards Lifesciences as confidence in growth profile begins to fadeFebruary 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM)February 2, 2023 | finance.yahoo.comEdwards Lifesciences Full Year 2022 Earnings: EPS Beats ExpectationsFebruary 1, 2023 | finanznachrichten.deEdwards Lifesciences Corporation: Edwards Lifesciences Reports Fourth Quarter ResultsFebruary 1, 2023 | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call TranscriptFebruary 1, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Q4 Earnings Top, Margins IncreaseFebruary 1, 2023 | finance.yahoo.comEdwards Lifesciences Surges As Signs Point To 'Green Shoots Around The Corner'February 1, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesFebruary 1, 2023 | benzinga.comEdwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Company Calendar Last Earnings1/31/2023Today3/25/2023Next Earnings (Estimated)4/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees17,300Year Founded1958Price Target and Rating Average Stock Price Forecast$88.95 High Stock Price Forecast$134.00 Low Stock Price Forecast$66.00 Forecasted Upside/Downside+10.1%Consensus RatingHold Rating Score (0-4)2.39 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$2.44 Trailing P/E Ratio33.10 Forward P/E Ratio32.05 P/E Growth4.76Net Income$1.52 billion Net Margins28.27% Pretax Margin32.84% Return on Equity26.05% Return on Assets18.36% Debt Debt-to-Equity Ratio0.10 Current Ratio3.03 Quick Ratio2.17 Sales & Book Value Annual Sales$5.38 billion Price / Sales9.09 Cash Flow$2.70 per share Price / Cash Flow29.90 Book Value$9.39 per share Price / Book8.60Miscellaneous Outstanding Shares606,100,000Free Float598,281,000Market Cap$48.95 billion OptionableOptionable Beta1.01 Social Links Key ExecutivesMichael A. MussallemChairman & Chief Executive OfficerBernard J. ZovighianPresidentScott B. UllemChief Financial Officer & Vice PresidentTodd J. BrintonChief Scientific Officer & VP-Advanced TechnologyLinda J. ParkSecretary, Senior VP & Associate General CounselKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNSmith & NephewNYSE:SNNView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 4,100 shares on 3/23/2023Ownership: 0.031%ETF Managers Group LLCBought 220 shares on 3/23/2023Ownership: 0.001%B. Riley Wealth Advisors Inc.Sold 4,854 shares on 3/15/2023Ownership: 0.006%Daveen ChopraSold 4,435 sharesTotal: $343,579.45 ($77.47/share)Michael A MussallemSold 19,875 sharesTotal: $1.54 M ($77.61/share)View All Insider TransactionsView All Institutional Transactions EW Stock - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price forecast for 2023? 18 brokers have issued 12 month price targets for Edwards Lifesciences' stock. Their EW share price forecasts range from $66.00 to $134.00. On average, they predict the company's stock price to reach $88.95 in the next year. This suggests a possible upside of 10.1% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2023? Edwards Lifesciences' stock was trading at $74.61 at the beginning of the year. Since then, EW shares have increased by 8.2% and is now trading at $80.76. View the best growth stocks for 2023 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 12,770,000 shares, an increase of 6.8% from the February 13th total of 11,960,000 shares. Based on an average daily volume of 3,940,000 shares, the short-interest ratio is presently 3.2 days. Currently, 2.1% of the company's stock are sold short. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings results on Tuesday, January, 31st. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.61 by $0.03. The medical research company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 26.05% and a net margin of 28.27%. The business's quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.51 EPS. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Goldman Sachs Future Health Care Equity ETF (GDOC), ETC 6 Meridian Quality Growth ETF (SXQG), Global X Aging Population ETF (AGNG), BNY Mellon Sustainable US Equity ETF (BKUS), Invesco S&P 500 Equal Weight Health Care ETF (RYH) and Inspire 100 ETF (BIBL). When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.45-$2.60 for the period, compared to the consensus estimate of $2.50. The company issued revenue guidance of $5.60-$6.0 billion, compared to the consensus revenue estimate of $5.78 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). What is Edwards Lifesciences' stock symbol? Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW." Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (3.60%), Moneta Group Investment Advisors LLC (2.49%), Brown Advisory Inc. (2.32%), Geode Capital Management LLC (1.96%), Norges Bank (1.43%) and Amundi (1.31%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Edwards Lifesciences' stock price today? One share of EW stock can currently be purchased for approximately $80.76. How much money does Edwards Lifesciences make? Edwards Lifesciences (NYSE:EW) has a market capitalization of $48.95 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.44 on an earnings per share basis. How many employees does Edwards Lifesciences have? The company employs 17,300 workers across the globe. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More How can I contact Edwards Lifesciences? Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525. This page (NYSE:EW) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.